sglt2 inhibitors and glp-1 receptor agonists together Combining in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique | Diabetes Therapy SGLT2 Inhibitors and GLP-1 Receptor
Description
Heerspink HJ, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al
doi: 10.1038/s41586-018-0849-9 59 RosarioWDAlessioD
Pfizers press release highlighted that Metsera brought four highly differentiated clinical-stage incretin and amylin programs (two injectables and two orals) to Pfizers portfolio ( [32] ) ( [11] )
Under him, Pfizer developed blockbusters like Eliquis and Prevnar
